Edgar Filing: CytomX Therapeutics, Inc. - Form 4

CytomX Thera Form 4 January 25, 20	•									
								OMB A	PPROVAL	
FORM	4 UNITED	STATES		RITIES A shington,			COMMISSIO	N OMB Number:	3235-0287	
Check this l if no longer subject to Section 16. Form 4 or		MENT OI		CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires: January 31 2005 Estimated average burden hours per response 0.5	
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940										
(Print or Type Res	sponses)									
1. Name and Address of Reporting Person <u>*</u> LADD CYNTHIA J			2. Issuer Name and Ticker or Trading Symbol CytomX Therapeutics, Inc. [CTMX			5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)	•	of Earliest Tr		L	(Che	eck all applicabl	e)	
(Mont			(Month/	(Month/Day/Year)			below)	Officer (give title Other (specify		
				led(Month/Day/Year) Applica _X_Fo			Applicable Line) _X_ Form filed by Form filed by	form filed by One Reporting Person filed by More than One Reporting		
FRANCISCO	, CA 94080						Person			
(City)	(State)	(Zip)	Tab	ole I - Non-D	erivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	Transaction Date Ionth/Day/Year)	Execution any	Date, if	3. Transaction Code (Instr. 8)	Disposed	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D) Price	(Instr. 3 and 4)			
Reminder: Report	t on a separate line	e for each cl	ass of sec	urities benefi	icially own	ned directly of	or indirectly.			
					inforn requir	nation cont ed to respo lys a curre	spond to the colle ained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab	le II - Deriv	vative Sec	curities Acqu	uired, Dis	posed of, or	Beneficially Owner	d		

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	iorDerivative	Expiration Date	Underlying Securities

Edgar Filing: CytomX Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (or Dispose (D) (Instr. 3, 4, and 5)	d of	(Month/Day	'Year)	(Instr. 3 and	4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 14.46	01/21/2016		A	45,000		<u>(1)</u>	01/20/2016	Common Stock	45,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
I G G G G G G G G G G G G G G G G G G G	Director	10% Owner	Officer	Other			
LADD CYNTHIA J 343 OYSTER POINT BLVD. SUITE 100 SOUTH SAN FRANCISCO, CA 94080			Senior VP and General Counsel				
Signaturas							

Signatures

/s/ Cynthia J. Ladd	01/25/2016		
<u>**</u> Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests in 48 substantially equal monthly installments starting on January 1, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.